NDAQ:ABVC - Post Discussion
Post by
whytestocks on May 24, 2024 8:30pm
Immunity Boosting Combination Therapy for Myelodysplastic Sy
NEWS: $ABVC Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50MUS FDA-IND 131300 (ABV-1702)   FREMONT, CA - ( NewMediaWire ) - May 24, 2024 -   ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncol...
ABVC - Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
Be the first to comment on this post